Search research articles
Contact Us
Filters
Showing results (51-60 of 217) with videos related to
Page
of 22
Sort By:
Cognitive Neuropsychiatry
|
July 28, 2009
Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations
Steven G Potkin, Jessica A Turner, Guia Guffanti, et al.
Schizophrenia Research
|
March 27, 2017
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation
Steven G Potkin, Robert Risinger, Yangchun Du, et al.
Clinical Therapeutics
|
December 28, 2002
Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability
Steven G Potkin, Per T Thyrum, Rimal Bera, et al.
Psychiatry Research. Neuroimaging
|
May 26, 2020
Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study
Theo Gm van Erp, Ross A Baker, Kevin Cox, et al.
The International Journal of Neuropsychopharmacology
|
May 8, 2009
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol
Steven G Potkin, Peter J Weiden, Antony D Loebel, et al.
Schizophrenia Research
|
February 19, 2013
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial
Antony Loebel, Josephine Cucchiaro, Kaushik Sarma, et al.
Schizophrenia Research
|
April 6, 2004
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
Philip D Harvey, Herbert Meltzer, George M Simpson, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
July 25, 2006
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
Elaine R Peskind, Steven G Potkin, Nunzio Pomara, et al.
Nuclear Medicine and Biology
|
April 25, 2006
Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate
Rama Pichika, Balasubramaniam Easwaramoorthy, Daphne Collins, et al.
The American Journal of Psychiatry
|
July 31, 2013
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010
Ofer Agid, Cynthia O Siu, Steven G Potkin, et al.
Page
of 22
Search research articles
Search
Showing results (51-60 of 217) with videos related to
Sort By:
Page
of 22
Cognitive Neuropsychiatry
|
July 28, 2009
Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations
Steven G Potkin, Jessica A Turner, Guia Guffanti, et al.
Schizophrenia Research
|
March 27, 2017
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation
Steven G Potkin, Robert Risinger, Yangchun Du, et al.
Clinical Therapeutics
|
December 28, 2002
Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability
Steven G Potkin, Per T Thyrum, Rimal Bera, et al.
Psychiatry Research. Neuroimaging
|
May 26, 2020
Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study
Theo Gm van Erp, Ross A Baker, Kevin Cox, et al.
The International Journal of Neuropsychopharmacology
|
May 8, 2009
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol
Steven G Potkin, Peter J Weiden, Antony D Loebel, et al.
Schizophrenia Research
|
February 19, 2013
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial
Antony Loebel, Josephine Cucchiaro, Kaushik Sarma, et al.
Schizophrenia Research
|
April 6, 2004
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
Philip D Harvey, Herbert Meltzer, George M Simpson, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
July 25, 2006
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
Elaine R Peskind, Steven G Potkin, Nunzio Pomara, et al.
Nuclear Medicine and Biology
|
April 25, 2006
Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate
Rama Pichika, Balasubramaniam Easwaramoorthy, Daphne Collins, et al.
The American Journal of Psychiatry
|
July 31, 2013
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010
Ofer Agid, Cynthia O Siu, Steven G Potkin, et al.
Page
of 22